Cargando…
Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States
PURPOSE: Patients with bone metastases are at an increased risk of experiencing morbidity due to bone complications, and bone-targeting agents (BTA) are indicated for the prevention of these complications. Population-based estimates of the prevalence of bone metastases associated with solid tumors,...
Autores principales: | Hernandez, Rohini K, Adhia, Avanti, Wade, Sally W, O’Connor, Emily, Arellano, Jorge, Francis, Kevin, Alvrtsyan, Hasmik, Million, Ryan P, Liede, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514316/ https://www.ncbi.nlm.nih.gov/pubmed/26229504 http://dx.doi.org/10.2147/CLEP.S85496 |
Ejemplares similares
-
Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States
por: Arellano, Jorge, et al.
Publicado: (2015) -
Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States
por: Hernandez, Rohini K., et al.
Publicado: (2018) -
Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States
por: Qian, Yi, et al.
Publicado: (2017) -
Validation of International Classification of Diseases coding for bone metastases in electronic health records using technology-enabled abstraction
por: Liede, Alexander, et al.
Publicado: (2015) -
Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US
por: McGrath, Leah J, et al.
Publicado: (2018)